In vivo and in vitro experiments proved that SETMAR can significantly facilitate the transcription of TTFs through the induction of SMARCA2‐mediated chromatin remodeling to affect the proliferation, EMT, RAI treatment uptake capacity, and sensitivity to MAPK inhibitor‐based redifferentiation therapies of thyroid cancer cells. Here, SMARCA2 is linked to thyroid cancer.